Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia

Journal of Intensive Care

Volumn 3, Issue 1, 2015, Pages

  Inchai, Juthamas ^a   Pothirat, Chaicharn ^a   Bumroongkit, Chaiwat ^a   Limsukon, Atikun ^a   Khositsakulchai, Weerayut ^b   Liwsrisakun, Chalerm ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b NAKORNPING HOSPITAL   (Thailand)

Author keywords

Extensively drug resistant A. baumannii; Mortality; Pandrug resistant A. baumannii; Prognostic factor; Ventilator associated pneumonia

Indexed keywords

CARBAPENEM; CEFOPERAZONE; COLISTIN; QUINOLONE DERIVATIVE; SULBACTAM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL GROWTH; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ASPIRATION; RETROSPECTIVE STUDY; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84979198391     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/s40560-015-0077-4     Document Type: Article

References (32)

1. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011, 184:1409-17. 10.1164/rccm.201102-0349OC, 21920919.
2. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007, 60:1163-7. 10.1093/jac/dkm305, 17761499.
3. Chaari A, Mnif B, Bahloul M, Mahjoubi F, Chtara K, Turki O, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013, 17:e1225-8. 10.1016/j.ijid.2013.07.014, 24094525.
4. Ozgur ES, Horasan ES, Karaca K, Ersoz G, Nayci Atis S, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control. 2014, 42:206-8. 10.1016/j.ajic.2013.09.003, 24485378.
5. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. 10.1164/rccm.200405-644ST.
6. Fujitani SC-MM, Tuttle RP, Delgado E, Taira Y, Darby JM. Comparison of semi-quantitative endotracheal aspirates to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-associated pneumonia. Respir Care. 2009, 54:1453-61. 19863828.
7. Hashimoto SSN. Evaluation of semi-quantitative scoring of Gram staining or semi-quantitative culture for the diagnosis of ventilator-associated pneumonia: a retrospective comparison with quantitative culture. J Intensive Care. 2013, 1:1-5. 10.1186/2052-0492-1-2.
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012, 18:268-81. 10.1111/j.1469-0691.2011.03570.x, 21793988.
9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
10. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol. 1997, 35:1394-7. 9163451.
11. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infectious Diseases 2010, 10:196. doi:10.1186/1471-2334-10-196, 10.1186/1471-2334-10-196, 20609238.
12. Kuo SC, Chang SC, Wang HY, Lai JF, Chen PC, Shiau YR, et al. Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect Dis 2012, 12:200. doi:10.1186/1471-2334-12-200, 10.1186/1471-2334-12-200, 22929085.
13. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008, 46:1254-63. 10.1086/529198, 18444865.
14. Richet H, Fournier P. Nosocomial infections caused by Acinetobacter baumannii: a major threat worldwide. Infect Control Hosp Epidemiol. 2006, 27:645-6. 10.1086/505900, 16807835.
15. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health?. Int J Antimicrob Agents. 2008, 32:106-19. 10.1016/j.ijantimicag.2008.02.013, 18571905.
16. Kollef KEGE, Angela RW, Richard MR, Scott TM, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. CHEST. 2008, 134:281-7. 10.1378/chest.08-1116, 18682456.
17. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002, 122:2115-21. 10.1378/chest.122.6.2115, 12475855.
18. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009, 302:2323-9. 10.1001/jama.2009.1754, 19952319.
19. Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, Dominguez-Herrera J, Fernandez-Cuenca F, Pachon J. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother. 2013, 57:4587-9. 10.1128/AAC.00543-13, 23836165.
20. Bahador A, Raoofian R, Taheri M, Pourakbari B, Hashemizadeh Z, Hashemi FB. Multidrug resistance among Acinetobacter baumannii isolates from Iran: changes in antimicrobial susceptibility patterns and genotypic profile. Microb Drug Resist. 2014, 20:632-40. 10.1089/mdr.2013.0146, 25029126.
21. Siempos II, Vardakas KZ, Kyriakopoulos CE, Ntaidou TK, Falagas ME. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock. 2010, 33:590-601. 10.1097/SHK.0b013e3181cc0418, 19953007.
22. Marechal H, Layios N, Damas P. The severity of ICU-acquired pneumonia. Curr Infect Dis Rep. 2013, 15:380-4. 10.1007/s11908-013-0359-8, 23949382.
23. Depuydt PO, Vandijck DM, Bekaert MA, Decruyenaere JM, Blot SI, Vogelaers DP, et al. Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care. 2008, 12:R142. 10.1186/cc7119, 19014695.
24. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vesin A, Garrouste-Orgeas M, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011, 184:1133-9. 10.1164/rccm.201105-0867OC, 21852541.
25. Lisboa T, Diaz E, Sa-Borges M, Socias A, Sole-Violan J, Rodriguez A, et al. The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest. 2008, 134:1208-16. 10.1378/chest.08-1106, 18779186.
26. Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Abroug F, Palizas F, et al. Incidence, risk factors, and outcome of ventilator-associated pneumonia. J Crit Care. 2006, 21:56-65. 10.1016/j.jcrc.2005.08.005, 16616625.
27. Daniels TL, Deppen S, Arbogast PG, Griffin MR, Schaffner W, Talbot TR. Mortality rates associated with multidrug-resistant Acinetobacter baumannii infection in surgical intensive care units. Infect Control Hosp Epidemiol. 2008, 29:1080-3. 10.1086/591456, 18837670.
28. Poulikakos P, Tansarli GS, Falagas ME. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis. 2014, 33:1675-85. 10.1007/s10096-014-2124-9, 24832022.
29. Gu WJ, Wang F, Tang L, Bakker J, Liu JC. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. Int J Antimicrob Agents. 2014, 44:477-85. 10.1016/j.ijantimicag.2014.07.004, 25199968.
30. Teixeira PJ, Seligman R, Hertz FT, Cruz DB, Fachel JM. Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. J Hosp Infect. 2007, 65:361-7. 10.1016/j.jhin.2006.12.019, 17350721.
31. Piskin N, Aydemir H, Oztoprak N, Akduman D, Comert F, Kokturk F, et al. Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: risk factors and impact on outcomes. BMC Infect Dis. 2012, 12:268. 10.1186/1471-2334-12-268, 23095664.
32. Lee SCHC, Yu TJ, Shieh WB, See LC. Risk factors of mortality for nosocomial pneumonia: importance of initial antimicrobial therapy. Int J Clin Pract. 2005, 59:39-45. 10.1111/j.1742-1241.2005.00281.x, 15707463.